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Abstract
Objective: Clinical options for managing nonmetastatic prostate cancer (PCa) vary.
Each option has side effects associated with it, leading to difficulty in decision-mak-
ing. This study aimed to assess the relationship between patient involvement in treat-
ment decision-making and subsequent decision regret (DR), and quantify the impact
of health-related quality of life (HRQL) outcomes on DR.
Methods:Men living in the United Kingdom, 18 to 42 months after diagnosis of PCa,
were identified from cancer registration data and sent a questionnaire. Measures
included the Decision Regret Scale (DRS), Expanded Prostate cancer Index Composite
short form (EPIC-26), EQ-5D-5L, and an item on involvement in treatment decision-
making. Multivariable ordinal regression was utilized, with DR categorized as none,
mild, or moderate/severe regret.
Results: A total of 17 193 men with stage I-III PCa completed the DRS: 36.6%
reported no regret, 43.3% mild regret, and 20.0% moderate/severe regret. The odds
of reporting DR were greater if men indicated their views were not taken into
account odds ratio ([OR] = 6.42, 95% CI: 5.39-7.64) or were involved “to some
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extent” in decision-making (OR = 4.63, 95% CI: 4.27-5.02), compared with men who
were “definitely” involved. After adjustment, including for involvement, men reporting
moderate/big problems with urinary, bowel, or sexual function were more likely to
experience regret compared with men with no/small problems. Better HRQL scores
were associated with lower levels of DR.
Conclusions: This large-scale study demonstrates the benefit of patient involvement in
treatment decision-making for nonmetastatic PCa. However, men experiencing side
effects and poorer HRQL report greater DR. Promoting engagement in clinical decision-
making represents good practice and may reduce the risk of subsequent regret.
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1 | BACKGROUND
Clinical decisions taken by patients and clinicians in choosing treat-
ment strategies for localized and locally advanced prostate cancer
(PCa) are complex.1,2 The range of clinical options that may be appro-
priate for an individual is diverse, including active surveillance, radical
radiotherapy, radical surgery, or androgen deprivation therapy (ADT).3
Where treatment options provide comparable levels of long-term
survival,3 the significant differences in toxicity4,5 and their impact on
the quality of survival need to be weighed up carefully in the
decision-making process, yet this is rarely straightforward.
Regret requires imagining possibilities other than the current
state being experienced, where individuals reflect on choices and out-
comes generated along with considering potential outcomes had the
choice been different.6 Previous studies exploring decision regret in
PCa survivors have been relatively small with the exception of a study
by Hoffman et al which included 900 patients.7 Recent systematic
reviews5,7,8 of the decision regret literature suggest studies are limited
by the timing of the evaluations carried out, are focused on localized
disease, and are limited to comparisons of one or two treatment
types. Some have assessed regret immediately after treatment when
side effects are unlikely to have developed, while others have evalu-
ated it many years after treatment was completed, when impaired
recall might became an issue.
Reviews suggest treatment side effects, such as sexual and uri-
nary dysfunction, and the overall level of patient well-being are all
associated with decision regret.4,8 Greater regret has been reported
more frequently in patients receiving radical prostatectomy than radi-
cal radiotherapy.4,5 Patient perception of having made an informed
choice (response to the question “I had all the information I needed
when a treatment was chosen for my prostate cancer”) was also
shown to be significantly associated with regret when patients were
evaluated 15 years after initial decision-making.7 For diseases other
than PCa, key risk factors for decision regret have included the nature
of the decision-making process, sociodemographic and treatment-
related variables, and poor mental health.5,9,10
As part of the Life After Prostate Cancer Diagnosis (LAPCD)
study,11 a UK-wide evaluation of quality of life outcomes in over
35 000 PCa survivors, we have collected information on the treat-
ments received, perceived involvement in treatment decision-making,
health-related quality of life (HRQL) outcomes, and decision regret.
With a focus on localized or locally advanced PCa, where men should
have some degree of choice over their treatment, we aimed to:
1. assess the relationship between involvement in treatment
decision-making and subsequent decision regret, in order to inform
best clinical practice at the time of initial treatment decision-
making;
2. quantify the impact of treatment side effects (urinary, bowel, and
sexual function) and HRQL on decision regret.
2 | METHODS
Men between 18 and 42 months after diagnosis of PCa were identi-
fied through cancer registration systems in England, Wales, and
Northern Ireland (NI) and through hospital activity data in Scotland. A
cross-sectional postal survey was mailed along with two reminders. In
England, 111 of 136 National Health Service (NHS) Trusts partici-
pated; 21 declined and 4 were involved in overlapping studies. All pro-
viders in NI (n = 5), Scotland (n = 14), and Wales (n = 6) participated.
The study protocol is available at https://bmjopen.bmj.com/content/
6/12/e013555. A copy of the survey is included as Supplementary
File 1. The LAPCD study design has been detailed previously.11
The study received approval (under section 251 of the NHS Act)
to contact men without prior informed consent. Along with the sur-
vey, all men received a detailed patient information sheet. Men con-
sented to take part in the study by returning completed surveys and
declined by not returning them, returning them unanswered, or opting
out via a free-phone helpline.
Respondents self-reported age, ethnicity (categorized as white or
nonwhite), marital status (categorized as married/civil partnership,
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separated/divorced, widowed, single, other), and presence of long-
term conditions (LTCs) from a list of comorbidities (counted and cate-
gorized as none, 1, 2, 3, and ≥4). Treatments were self-reported from
a list of possible options and categorized into single therapies (eg,
external beam radiotherapy [EBRT] alone) or combinations therapies
(eg, EBRT and ADT). Active surveillance and watchful waiting were
combined into a “monitoring” category as we believe there was some
confusion in understanding the difference between the terms.12,13
Stage at diagnosis was obtained from the cancer registration records.
Stages I and II were combined into a “localized disease” group and
stage III were defined “locally advanced.” A measure of socioeconomic
deprivation was derived using area of residence.14-17
Respondents reported their perceived level of involvement in
their treatment decision-making process. This item was taken from
the 2014 National Cancer Patient Experience Survey18: “Do you think
your views were taken into account when the team of doctors and
nurses caring for you were discussing which treatment you should
have?” This item had five response categories (Yes, definitely; Yes, to
some extent; No, my views were not taken into account; I didn't know
my treatment was being discussed; Not sure/can't remember).
The Expanded Prostate cancer Index Composite short form (EPIC-
26)19 measures function across five domains (urinary incontinence, uri-
nary irritation and obstruction, bowel, sexual, and vitality/hormone).
Three items relating to the overall level of problems with urinary, bowel,
or sexual function were used, with responses categorized as no/small
problem and moderate/big problem. The impact of hormone problems
was omitted from analysis due to data collection limitations (hormone
problems are strongly linked to ADT use but the survey did not ask
whether men were on ADT currently/previous to the time of survey).
EQ-5D-5L20,21 records information on five dimensions plus a rating
of self-assessed health (SAH) based on the statement “We would like to
know how good or bad your health is today” (valued 0-100, where
100 represents best possible health). Mean SAH ratings were calculated.
The Decision Regret Scale (DRS) is a validated measure of decision
regret.22 The scale includes five items (It was the right decision; I regret
the choice that was made; I would go for the same choice if I had to do
it over again; The choice did me a lot of harm; The decision was a wise
one) each rated on a five-point scale. Scores range from 0 to 100 and
are calculated in increments of 5. While there are no defined cutoff
points for the scale, a recent paper suggested the following cutoff
points: No regret 0, Mild regret 5 to 25, and Moderate/severe
regret ≥30.23
2.1 | Statistical analysis
Descriptive statistics (chi-square tests) were used to compare the
characteristics of men who did and did not complete the DRS, and to
compare the men who reported different levels of regret (no regret,
mild, and moderate/severe23). Multivariable ordinal regression was
performed, with the three categories of decision regret as the out-
come variable, which allowed the comparison of mild/moderate/
severe regret vs no regret and moderate/severe regret vs mild/no
regret. Ordinal regression assumes there is a natural order to the out-
come (regret) but the distances between the levels are unknown.
Directed acyclic graphs (DAGs) were used to identify appropriate
adjustment variables for each model. First, the association between
involvement in the decision-making process and subsequent regret
was assessed. This model was adjusted for age, ethnicity, marital sta-
tus, number of other LTCs, socioeconomic deprivation quintile, and
stage of disease as informed by the DAG (Figure S2). Second, associa-
tions between HRQL and decision regret were assessed using sepa-
rate models to look at urinary function, bowel function, sexual
function, and self-assessed health. A combined model looked at the
reporting of any functional problem (urinary, and/or bowel, and/or
sexual) as men may experience more than one treatment side effect.
All HRQL models were adjusted for age, marital status, number of
other LTCs, socioeconomic deprivation quintile, treatment type and
level of involvement in treatment decision-making (Figure S4). Data
were analyzed using Stata version 15 (StataCorp, Texas).
3 | RESULTS
3.1 | Study population
In total, 35 823 men completed a survey (response rate 60.8%,
responder and nonresponder characteristics reported in Table S1).
The full sample has been described elsewhere.24 For the purposes of
this study, we focused on men with stage I-III PCa who reported
receiving one of the eight most common treatments (Table S2). Men
were excluded if they were diagnosed with stage IV disease
(n = 3925), had no stage recorded by the national cancer registration
system (n = 5090), reported receiving systemic therapy (n = 320),
were unsure about the type of treatment they received (n = 2580) or
reported a nonstandard or rare treatment combination (n = 1362).
This left a total of 22 358 men, of whom 17 193 (76.9%) answered all
five items on the DRS. The level of missing data was low for DRS item
1 (3.8%) but was higher (14.7-21.2%) for the other four items (-
Table S3); 12.5% of men answered the first DRS item only. Men were
less likely to complete the DRS if they were older, nonwhite,
widowed, lived in a more deprived area or were treated with EBRT
alone or ADT alone (Table S4).
Table S2 shows the characteristics of respondents to the DRS.
The median age at time of survey was 70 years (Interquartile range
IQR: 65-75). Three quarters (74.1%, n = 12 748) were diagnosed with
localized (stage I/II) disease and 25.9% (n = 4445) had stage III cancer.
The most commonly reported treatments were combined EBRT &
ADT (28.1%, n = 4839), surgery alone (28.1%, n = 4824), and monitor-
ing (17.6%, n = 3028).
3.2 | Decision regret
Just over a third of men (36.6%, n = 6297) reported they had no deci-
sion regret, 43.3% (n = 7450) reported mild regret, and 20.0%
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(n = 3446) reported moderate/severe regret. The characteristics of
men reporting different levels of regret are reported in Table S2.
Older, nonwhite, separated/divorced or single men, those with other
LTCs, and those living in more deprived areas reported higher levels
of decision regret. Men who reported receiving ADT alone or in com-
bination with other treatments had higher levels of regret.
3.3 | Involvement in treatment decision-making
and subsequent decision regret
The majority of men felt their views had “yes, definitely” been taken
into account in treatment decision-making (73.9%; n = 12 574). A fur-
ther 18.1% (n = 3077) reported they had been involved “yes, to some
extent”, while 3.2% (n = 545) reported their views had not been taken
into account, and 4.9% (n = 829) were unsure about their involvement
in decision-making (didn't know treatment was being discussed/not
sure/can't remember). Men who said they were definitely involved in
their treatment decision-making reported lower levels of regret:
44.6% reported no decision regret, 43.3% reported low regret, and
12.1% reported moderate or high regret (Figure 1). Men who said they
were involved “to some extent” reported higher levels of decision
regret (no regret: 14.3%; low regret: 45.5%; and moderate/high
regret: 40.1%), as did those who said their views were not taken into
account (no regret: 15.4%; low regret: 33.8%; and moderate/high
regret: 50.8%) (Figure 1).
After adjustment for factors known at the time of treatment
decision-making (including age, ethnicity, number of other LTCs,
socioeconomic deprivation quintile, and stage of disease), the odds of
reporting decision regret were greater if men indicated “no, my views
were not taken into account” (OR = 6.42; 95% CI: 5.39-7.64), or they
were involved “yes, to some extent” (OR = 4.63; 95% CI: 4.27-5.02)
compared with men who reported they were “yes, definitely” involved
in decision-making (Table S5).
3.4 | The association between quality of life
outcomes and decision regret
Overall, 43.9% of men reported that their sexual function was a mod-
erate/big problem. The corresponding figures for urinary and bowel
function were 12.0% and 7.9%. Men who reported more severe prob-
lems with function experienced higher levels of decision regret (Table 1).
Men with greater decision regret had lower mean SAH scores.
Men may report problems in multiple functional domains and
therefore a composite variable was created which included men who
reported moderate/severe problems with urinary, bowel, or sexual
function. Of the 16 171 men who answered all three items, 49.9%
reported one or more moderate/big functional problems. Men with
any moderate/big functional problems reported higher levels of deci-
sion regret (Table 1).
In the men who said they were “definitely” involved in treatment
decision-making, 53.0% (n = 6292) reported no or small problems with
urinary, bowel, or sexual function and 47.0% (n = 5592) reported one
or more moderate/big problem. Figure S1 shows the level of decision
regret in these groups. Moderate/severe regret was experienced by
7.7% (n = 484) of the no/small functional problems group and 17.1%
(n = 957) of the moderate/big functional problems group.
In the men who said their views were not taken into account or
they were involved “to some extent” in treatment decision-making,
F IGURE 1 Involvement in
treatment decision-making and
experience of decision regret
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42.3% (n = 1749) reported no or small urinary, bowel, or sexual
problems and 57.7% (n = 2390) reported one or more moderate/big
problem. Moderate/severe regret was experienced by 29.2%
(n = 511) of the no/small functional problems group and 51.1%
(n = 1221) of the moderate/big functional problems group
(Figure S1).
After adjustment for relevant patient characteristics, treatment
and involvement in decision-making, poorer quality of life outcomes
were associated with greater decision regret (Table 2). For example,
reporting moderate/big problems with bowel function was associated
with 2.5 times higher odds of experiencing regret (OR = 2.49, 95% CI:
2.22-2.79) compared with those reporting no or small problems. The
ORs for decision regret in men reporting moderate/big problems with
urinary function and sexual function were 2.31 (95% CI: 2.10-2.54)
and 1.93 (95% CI: 1.81-2.05), respectively, compared with those
reporting no or small problems. In men reporting problems with uri-
nary, bowel, or sexual function, the OR of experiencing decision regret
was 2.13 (95% CI: 2.00-2.26). Higher SAH scores were associated
with a reduction in the odds of reporting decision regret (OR = 0.98,
95% CI: 0.98-0.98 per point increase in SAH).
4 | DISCUSSION
To the best of our knowledge, this is the largest study of decision
regret in PCa survivors to date. It includes just under 6000 men with
locally advanced disease, a group typically excluded from studies of
decision regret, yet who can expect to live for long periods following
diagnosis and may be offered treatment choices. Overall, 63% of men
reported some level of decision regret regarding their treatment
choice. There was a strong association between a perceived lack of
involvement in the treatment decision-making process and greater
levels of subsequent decision regret. Men who experienced treatment
side effects (poor urinary, bowel, or sexual function) and lower self-
assessed HRQL also reported greater regret about their treatment
decision, although the levels of regret were lower in the men who felt
they were involved in the decision-making. Initiatives to promote and
support active patient engagement in clinical decision-making repre-
sent good practice and may serve to reduce the risk of subsequent
decision regret.
While previous findings from smaller studies have been mixed
regarding the association between patient involvement and
TABLE 1 Functional outcomes and level of decision regret
Level of decision regret
None Mild Moderate/severe Total
Moderate/big urinary problema (n = 17 068)
No 5844 6560 2621 15 025
38.9% 43.7% 17.4% 100%
Yes 418 840 785 2043
20.5% 41.1% 38.4% 100%
Moderate/big bowel problema (n = 17 089)
No 6011 6876 2851 15 738
38.2% 43.7% 18.1% 100%
Yes 244 543 564 1351
18.1% 40.2% 41.8% 100%
Moderate/big sexual problema (n = 16 307)
No 3929 3906 1323 9158
42.9% 42.7% 14.5% 100%
Yes 2035 3168 1946 7149
28.5% 44.3% 27.2% 100%
Any moderate/big functional problemb (n = 16 171)
No 3651 3445 1009 8105
45.0% 42.5% 12.4% 100%
Yes 2272 3577 2217 8066
28.2% 44.3% 27.5% 100%
Self-assessed healthc (n = 16 938)
Mean rating 82.7 78.0 71.3 78.4
aDerived from EPIC-26 items “Overall, how big a problem has your urinary function/bowel habits/sexual function been for you during the last 4 weeks?”
bComposite variable created including men who reported moderate/severe problems with urinary, bowel, or sexual function.
cDerived from EQ-5D Visual Analogue Scale “We would like to know how good or bad your health is today” (range 0-100, where 100 represents the best
health you can imagine).
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regret,25,26 this study found the odds of experiencing regret were sig-
nificantly greater if men indicated their views had not been fully taken
into account. This is in keeping with an earlier finding from a smaller
sample at a much later time point (15 years) from treatment.7 In the
LAPCD study, approximately one in five men reported moderate or
severe regret which is higher than in previous studies.8,25,27 One
potential explanation for this is the inclusion of men with locally
advanced disease as well as the full range of treatment types, whereas
previous studies have typically focused on one or two treatment types
and those with localized disease. In particular, the inclusion of men
who have received ADT, which has been associated with poorer func-
tional24 and psychological outcomes28 may have increased the magni-
tude of decision regret being reported.
The strengths of this study lie in its large size and inclusion of the
whole population, unbiased by clinical trial selection and not limited
by treatment type. Men were between 18 and 42 months after diag-
nosis, close enough to diagnosis to enable accurate recall but with suf-
ficient time for the potential adverse functional outcomes of
treatment to have developed and stabilized.
4.1 | Study limitations
All measures were completed at the same time and may be sub-
ject to mood-related effects on that specific day. In particular,
recall bias may have influenced the responses given, where survi-
vors prior and/or present experiences of side effects may have
altered retrospective recall of the decision-making process.29 Just
over 60% of men responded to the survey and a quarter of these
men did not fully complete the regret scale, hence there may be
systematic differences between responders and nonresponders.
Men with the poorest outcomes may have been unwilling or
unable to complete the survey. Additionally, there were high
levels of missing data with up to 20% missing on some items of
the DRS. Previous studies using the DRS in PCa have typically
questioned individuals in a clinical setting and therefore had little
or no missing data. Only men who answered all five components
of the DRS were included in this analysis. To our knowledge, this
is the largest study to date to use the DRS in a cross-sectional
survey and therefore demonstrates some of the limitations of
using this measure.
It may be the case that some men did not feel they had an active
“choice” over treatment due to the stage of their disease or other clin-
ical factors. Importantly, men were not asked how involved they
wanted to be in their treatment decision-making. In-depth qualitative
work has demonstrated that not all men were confident or happy in
making decisions about their treatment.30 For those men with locally
advanced disease (stage III) we do not know if they were offered a
treatment choice and so there may be conflation between “treatment
decision regret” and “treatment regret.”
TABLE 2 Multivariable ordinal
regression analyses of the association
between health-related quality of life
factors and decision regret
Functional outcome n % Adjusted ORa 95% CI
Moderate/big urinary problemb
No 15 025 88.0 1.00
Yes 2043 12.0 2.31 2.10-2.54
Moderate/big bowel problemb
No 15 738 92.1 1.00
Yes 1351 7.9 2.49 2.22-2.79
Moderate/big sexual problemb
No 9158 56.2 1.00
Yes 7149 43.8 1.93 1.81-2.05
Any moderate/big functional problem
No 8105 50.1 1.00
Yes 8066 49.9 2.13 2.00-2.26
Self-assessed healthc (Mean)
Per unit increase in score 16 938 78.4 0.98 0.98-0.98
Abbreviations: CI, Confidence Interval; OR, Odds ratio.
aThe ordinal regression results compare mild/moderate/severe regret vs no regret and moderate/severe
regret vs mild/no regret). Models adjusted for age, marital status, number of other long-term conditions,
socioeconomic deprivation quintile, treatment type, and level of involvement in treatment decision-
making.
bDerived from EPIC-26 items “Overall, how big a problem has your urinary function/bowel habits/sexual
function been for you during the last 4 weeks?”
cDerived from the EQ-5D Visual Analogue Scale “We would like to know how good or bad your health is
today” (range 0-100, where 100 represents the best health you can imagine). This is a continuous
variable with results presented as the odds of experiencing decision regret for each unit increase in the
self-assessed health score.
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Due to limitations with cancer registry treatment data, this was
self-reported and therefore relies on accurate recall. A small propor-
tion of men indicated that they had received ADT only. This may be
appropriate in some cases,31 but it may also be that men did not
report all their received treatments. Cancer registry data do not cur-
rently include information on disease progression or recurrence;
therefore, we did not have up-to-date information on disease stage at
the time of survey completion. Related to this, we do not know if men
had additional treatment at a later date because of disease progres-
sion or nonresponse to initial treatment. A lack of detailed information
on ADT use (eg, timing and duration) meant we were unable to evalu-
ate the impact of hormone function on decision regret. Finally, we
were not able to obtain data on time since diagnosis, which may have
influenced men's experience of regret.
4.2 | Clinical implications
This study reinforces the need for clinicians to fully explain the likely
consequences of different treatment options, including specific func-
tional problems, during up-front decision-making consultations. Men
with PCa, and partners or family members where possible and appro-
priate, should be actively involved in discussions about their treat-
ment. Clinicians caring for men with PCa should be reassured that
patient involvement in decision-making is not only intuitively repre-
sentative of best practice but may also enhance quality of survival
through reduced subsequent decision regret.
5 | CONCLUSIONS
This large-scale study provides evidence of the benefit of patient
involvement in treatment decision-making for localized and locally
advanced PCa. However, due to the nature of the treatments involved,
there will always be a group of men who experience treatment-related
late effects, and appropriate support should be available to reduce the
impact of these late effects on their wider quality of life.
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